SAN DIEGO, Oct. 18, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid testing
designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, announces
the launch of its molecular pathology partnership initiative, the
aim of which is to incorporate community pathologists into the
review of biomarkers found in liquid biopsy for patients diagnosed
with cancer. Patient specimens will continue to be sent to Biocept
for processing in its CLIA-certified, CAP-accredited
laboratory.
"Having pathologists involved in the interpretation of liquid
biopsy is important, as community physicians and hospitals want to
take advantage of leading-edge medical solutions by providing the
best patient care in their local health system," said Michael Terry, Senior Vice President, Commercial
Operations at Biocept. "Combining liquid biopsy and the expertise
of the local pathologist can provide better overall continuity of
care when it comes to cancer diagnosis and treatment as they are
the one of the first to know when a patient could benefit from a
liquid biopsy. Our initial roll-out of this program showed strong
acceptance by pathologists and clinicians, and we are now beginning
to offer this program to additional cancer treatment centers around
the country."
"We believe that local pathologists will value Biocept's ability
to provide them with access to proprietary liquid biopsy
technology, and we are looking forward to expanding and building
new relationships in hospitals around the country with this
program," said Biocept's President and Chief Executive Officer
Michael Nall. "We continue to
execute on expanding our physician services and our menu of
non-invasive biomarker tests, in addition to our objective to
increase the number of cancer indications addressed by our
platform, making Biocept the go-to choice in liquid biopsy."
Biocept's Target Selectorâ„¢ liquid biopsy tests are performed in
its CLIA-certified, CAP-accredited laboratory located in
San Diego, California. To order a
liquid biopsy test or participate in the Pathology Partnership
program, please contact Customer Service at 888-332-7729 or
customerservice@biocept.com.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company
leverages its proprietary liquid biopsy technology to provide
physicians with clinically actionable information for treating and
monitoring patients diagnosed with cancer. Biocept's patented
Target Selectorâ„¢ liquid biopsy technology platform captures and
analyzes tumor-associated molecular markers in both circulating
tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic options. For
additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
news release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to our ability to
identify specific clinical conditions or improve the outcomes of
cancer patients, the utility and effectiveness of our intellectual
property protections, the financial impact of new contracts, and
our ability to increase the number of products or services provided
or the value of the Company, such statements are forward-looking,
and are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risk factors as set forth
in our Securities and Exchange Commission (SEC) filings. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this news release. We do not plan to update any such
forward-looking statements and expressly disclaim any duty to
update the information contained in this press release except as
required by law. Readers are advised to review our filings with the
SEC at www.sec.gov
Investor
Contact: Media
Contact:
LHA Investor
Relations Trevelino/Keller
Jody
Cain Colleen
Murphy
Jcain@lhai.com cmurphy@trevelinokeller.com
310-691-7100 404-214-0722,
Ext. 109
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocept-launches-pathology-partnership-initiative-expanding-access-of-proprietary-liquid-biopsy-testing-to-community-pathologists-and-hospitals-300538625.html
SOURCE Biocept, Inc.